Welcome to our dedicated page for Spyre Therapeutics news (Ticker: SYRE), a resource for investors and traders seeking the latest updates and insights on Spyre Therapeutics stock.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The SYRE news page on Stock Titan aggregates company press releases, clinical updates, and capital markets announcements so readers can follow how Spyre’s programs and corporate activities evolve over time.
In its public communications, Spyre highlights a pipeline of investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23, with programs such as SPY001, SPY002, SPY072, and SPY003. News items frequently cover interim Phase 1 data, such as reports that SPY003 was well tolerated and exhibited an approximately 85-day half-life, and that SPY002 and SPY072 showed pharmacokinetic profiles supporting potential quarterly or twice-yearly maintenance dosing. Updates also describe the design and enrollment status of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
Investors and followers of SYRE can also find announcements about stock offerings, use of proceeds, and equity inducement awards granted under the company’s equity plans, as well as participation in scientific congresses and investor conferences. Together, these news items provide insight into Spyre’s clinical development progress, financing activities, and broader corporate strategy as disclosed by the company.
For users tracking SYRE, this page offers a centralized view of Spyre Therapeutics’ official news flow, including trial milestones, interim study findings, and key financing events drawn from press releases and related disclosures.
Spyre Therapeutics (NASDAQ: SYRE) outlined a 2026 plan anchored by six expected proof-of-concept (POC) readouts: three from the SKYLINE Phase 2 platform in ulcerative colitis and three from the SKYWAY Phase 2 basket trial in RA, PsA, and axSpA. Enrollment for SKYLINE Part A exceeded expectations with SPY001 enrollment complete and Part A readouts now anticipated to begin in Q2 2026. SKYWAY readouts across all indications are expected in 4Q 2026. The company appointed Kate Tansey Chevlen as Chief Commercial Officer and reported a pro forma cash, cash equivalents, and marketable securities balance of $783M as of Sept 30, 2025, which it expects to fund operations into the second half of 2028.
Spyre Therapeutics (NASDAQ: SYRE) announced inducement equity awards: stock options to purchase an aggregate of 42,000 shares granted to six non-executive employees under the 2018 Equity Inducement Plan. The grants were approved on January 2, 2026 and were described as material to each employee's acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have a 10-year term, an exercise price of $30.58 (Spyre closing price on January 2, 2026), and vest one-fourth on the first anniversary of each employee’s start date with the remainder vesting monthly at 1/48th thereafter, subject to continuous service and the terms of the 2018 Plan.
Spyre Therapeutics (NASDAQ: SYRE) announced that its independent Compensation Committee approved inducement stock option awards to two non-executive employees under the Spyre 2018 Equity Inducement Plan.
The awards total 20,300 options, were approved on December 1, 2025, have a 10-year term, and an exercise price of $28.66 (Nasdaq closing price on December 1, 2025). Vesting is one-quarter on the first anniversary of each employee’s start date and then 1/48th monthly thereafter, subject to continuous service; the options are subject to the 2018 Plan and were described as material to each employee’s acceptance under Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics (NASDAQ: SYRE) announced that its independent Compensation Committee approved inducement stock options for 19,600 shares to one non-executive employee under the 2018 Equity Inducement Plan. The grants were approved on November 3, 2025, have a 10-year term, and an exercise price equal to the $23.78 Nasdaq closing price on November 3, 2025. Vesting is one-fourth on the first anniversary of the employee’s start date and then 1/48th monthly thereafter, subject to continuous service. The options were described as material to the employee’s acceptance of employment under Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics (NASDAQ:SYRE) reported Q3 2025 results and program updates on Nov 4, 2025. Key developments include positive Phase 1 interim data for SPY003 (IL-23) showing a ~85-day half-life supporting quarterly or twice‑annual dosing, and interim Phase 1 data for SPY002/SPY072 showing complete TL1A suppression through up to 20 weeks.
The company initiated the SKYWAY Phase 2 basket trial (SPY072) in Sept 2025 and the SKYLINE Phase 2 platform (SPY001/SPY002; SPY003 expected soon). Spyre expects six Phase 2 proof‑of‑concept readouts in 2026. Financings: $316M gross from an underwritten offering and pro forma cash of $782.7M as of Sept 30, 2025, with expected runway into H2 2028.
Spyre Therapeutics (NASDAQ: SYRE) announced positive interim Phase 1 results for SPY003, an extended half-life anti-IL-23 antibody, from a first-in-human randomized, double-blind, placebo-controlled study in 59 healthy volunteers (data cutoff Sept 19, 2025).
Key findings: ~85-day half-life (more than 3x risankizumab), dose-proportional PK, limited intrasubject variability, no serious adverse events, two ≥Grade 2 TEAEs deemed not treatment-related, and no apparent anti-drug-antibody impact on PK. Results support potential quarterly or twice-annual SC maintenance dosing and progression into the SKYLINE Phase 2 platform and additional combination programs.
Spyre Therapeutics (NASDAQ: SYRE) announced that management will participate in three investor conferences in November 2025: the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on Nov 10, 2025 at 10:00 am ET, the Stifel 2025 Healthcare Conference in New York on Nov 11, 2025 at 8:40 am ET, and the Jefferies Global Healthcare Conference in London on Nov 19, 2025 at 8:00 am GMT. Live audio webcasts and replays will be available on the company’s investor events website at https://ir.spyre.com/events-and-presentations.
Spyre Therapeutics (NASDAQ: SYRE) announced poster presentations at ACR Convergence 2025 on Oct 24, 2025 covering interim Phase 1 and preclinical data for SPY072.
Key points: six‑month follow‑up from the Phase 1 study shows SPY072 was reported as well tolerated, demonstrated a differentiated pharmacokinetic profile supporting quarterly (Q3M) or twice‑yearly (Q6M) dosing, and suppressed free TL1A through 20 weeks at the lowest dose. Preclinical rodent data were presented showing anti‑TL1A treatment met or exceeded etanercept efficacy in a collagen‑induced arthritis model. Posters relate to the ongoing SKYWAY Phase 2 basket study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Posters are available via the ACR program.
Spyre Therapeutics (Nasdaq: SYRE) announced the closing of an underwritten public offering on Oct 15, 2025 of 17,094,594 shares of common stock, including the full exercise of a 2,229,729‑share underwriter option, at $18.50 per share. The offering generated approximately $316.2 million in gross proceeds before underwriting discounts, commissions and offering expenses. A Form S‑3 registration (File No. 333‑285341) became effective on Mar 7, 2025. Joint book‑running managers included Jefferies, TD Securities, Leerink Partners and Stifel; Wedbush acted as lead manager.
Spyre Therapeutics (NASDAQ: SYRE) priced an underwritten public offering of 14,864,865 common shares at $18.50 per share, expected to generate approximately $275.0 million in gross proceeds before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 2,229,729 shares at the public offering price.
The offering is expected to close on or about October 15, 2025, subject to customary closing conditions. A registration statement (Form S-3, File No. 333-285341) became effective on March 7, 2025.
FAQ
What is the current stock price of Spyre Therapeutics (SYRE)?
What is the market cap of Spyre Therapeutics (SYRE)?
